Table I.
Clinical characteristics of patients treated with sorafenib and hepatic arterial infusion chemotherapy (HAIC).
| Variables | Sorafenib (n=12) | HAIC (n=8) | P-value |
|---|---|---|---|
| Age (years) | 80.2±5.4 | 74.9±3.4 | 0.039a |
| Gender (M/F) | 6/6 | 6/2 | NSb |
| White cell count (×102/μl) | 48.0±13.2 | 59.4±27.4 | NSa |
| Lymphocyte count (×102/μl) | 14.6±8.5 | 14.9±6.2 | NSa |
| Platelet count (×104/μl) | 16.7±6.1 | 14.1±6.7 | NSa |
| PT-INR | 1.10±34.6 | 1.16±0.19 | NSa |
| ALT (IU/l) | 35.5±0.12 | 41.9±0.19 | NSa |
| Total bilirubin (mg/dl) | 0.67±0.40 | 0.76±0.27 | NSa |
| Albumin (g/dl) | 3.5±0.4 | 3.3±0.8 | NSa |
| Cirrhosis (Child-Pugh A/B/C) | 10/2/0 | 4/4/0 | NSb |
| TNM stage (I/II/III/IV-A/IV-B) | 0/2/3/2/5 | 0/2/3/2/1 | NSc |
| Largest tumor (mm) | 42.3±21.2 | 49.7±28.2 | NSa |
| AFP | 2,027±5,219 | 279±418 | NSa |
Results are expressed as means ± standard deviation.
a
Mann-Whitney U test.
b
Fisher’s exact test.
c
Chi-square test.
M, male; F, female; NS, non-significant; PT-INR, prothrombin time-international normalized ratio; ALT, alanine aminotransferase; Child-Pugh, Child-Pugh classification; TNM, tumor-node-metastasis; AFP, α-fetoprotein.